Literature DB >> 25475431

Follicular lymphoma presenting with hypercalcaemia: an unusual mechanism of hypercalcaemia.

P Martens, B Addissie, R Kumar.   

Abstract

Hypercalcaemia is a frequent finding in patients with cancer. In up to 30% of malignancies, the disease course is complicated with hypercalcaemia. For hospitalized patients, cancer is the most common cause of hypercalcaemia. In normal physiological circumstances, the ionized calcium is kept in check by the influence of two important hormones, parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (1,25(OH)2D). However, cancer can misbalance the calcium homeostasis by generating certain humoural mediators. Overproduction of parathyroid hormone-related peptide (PTH-rp), intact PTH, 1,25(OH)2D, and cytokines all cause hypercalcaemia. Hypercalcaemia is frequent in certain haematological cancers such as multiple myeloma and aggressive lymphomas. But hypercalcaemia is rare in patients with indolent lymphomas such follicular lymphoma. This case illustrates as a first to our knowledge the involvement of cytokines and chemokines in the pathophysiology of lymphoma-related hypercalcaemia. A pathophysiological mechanism is offered based upon the current understanding of cytokines and chemokines related to follicular lymphoma.

Entities:  

Keywords:  Hypercalcaemia,; Indolent lymphoma,; Pathophysiology

Mesh:

Substances:

Year:  2014        PMID: 25475431     DOI: 10.1179/2295333714Y.0000000106

Source DB:  PubMed          Journal:  Acta Clin Belg        ISSN: 1784-3286            Impact factor:   1.264


  3 in total

1.  Methotrexate-induced iatrogenic immunodeficiency-associated lymphoproliferative disorder causing hypercalcaemia.

Authors:  Monica Lee; Khoa Anh Nguyen; Robert Kaplan
Journal:  BMJ Case Rep       Date:  2019-05-31

2.  HYPERCALCEMIA OF MALIGNANCY IN A CASE OF PERIPHERAL NERVE SHEATH TUMOR: ELUCIDATING THE ROLES OF SIMULTANEOUS MECHANISMS.

Authors:  Malini Ganesh; Sanford Baim
Journal:  AACE Clin Case Rep       Date:  2020-05-08

3.  Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies.

Authors:  Cheng Cheng; Jose Kuzhively; Sanford Baim
Journal:  Case Rep Endocrinol       Date:  2017-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.